MedTrace Logo

Benefit of IQP-VV-102 in Reducing Postprandial Glucose Level in Overweight Caucasian Subjects

NCT02541344 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2015-11-10

No results posted yet for this study

Summary

In this trial, the investigational product , the active ingredients which has been proven to reduce postprandial glucose in healthy and diabetic patients, will be tested. The primary aim of this clinical study is to evaluate the possibility of the investigational product to reduce the rise of postprandial glucose AUC level in overweight Caucasian subjects with normal to prediabetic biomarkers (IFG/HbA1C), without prompting a disproportionate rise in insulin levels.

Conditions

Interventions

DEVICE

Dose 1 of IQP-VV-102

Dose 1 (D1) group will take 2 tablets with active ingredients and 2 placebo tablets.

DEVICE

Dose 2 of IQP-VV-102

Dose 2 (D2) group will take 4 tablets with active ingredients.

DEVICE

Placebo

Placebo group will take 4 placebo tablets. The placebo is designed to be identical to IQP-VV-102.

Sponsors & Collaborators

  • InQpharm Group

    lead INDUSTRY

Principal Investigators

  • Ralf Uebelhack, PhD · Charite

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2015-10-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02541344 on ClinicalTrials.gov